OpenEvidence
also referred to as: open evidence
14 statements across 3 episodes · 12 bullish · 0 bearish · 3 people on the record · first statement Aug 21, 2025 by Sarah Guo · said 41 times in 10 episodes since 2025 · across every show →
Mentions by year
brought up most by Sarah Guo (19), Daniel Nadler (10), Jensen Huang (4), Elad Gil (4), Gabe Pereyra (1)
tap a year for its mentions
2026 11 mentions in 4 episodes 3 per episode
- NVIDIA’s Jensen Huang on Reasoning Models, Robotics, and Refuting the “AI Bubble” Narrative
- Baseten CEO Tuhin Srivastava on Custom Models, and Building the Inference Cloud
- Chasing Trillion-Dollar Companies, Founder Ambition, Token Budgets, & Regulatory Capture
- We Need An Ecosystem in AI, And Every Company Can Win A Place In It
- every mention in 2026, scene by scene →
2025 30 mentions in 6 episodes 5 per episode
- No Priors Ep. 130 | With OpenEvidence Founder Daniel Nadler
- No Priors Ep. 128 | With Andrew Ng, Managing General Partner at AI Fund
- No Priors Ep. 144 | The 2026 AI Forecast with Sarah & Elad
- No Priors Ep. 142 | With Harvey Co-Founder and President Gabe Pereyra
- No Priors Ep. 117 | With Co-Director of Stanford's HAI & Founder of World Labs Dr. Fei-Fei Li
- No Priors Ep. 116 | With Sarah and Elad
- every mention in 2025, scene by scene →
Everything said about OpenEvidence, oldest first
Aug 21, 2025 bullish
Guo: Open Evidence reaches 50% of US doctors while keeping headcount minimal
“I work with several teams now one of which is called Open Evidence and has, like, a pretty good penetration, like, 50% of doctors in the U.S. Now, where it's an explicit objective in the company to try to be as small as possible.”
Sep 5, 2025
Sep 5, 2025 positive
Sep 5, 2025 positive
Nadler: Top hospital CEOs and chief medical officers use OpenEvidence personally
“So the entire, you know, the, this whole senior leadership of UCSF, of MGH, of Mayo Clinic, of Cleveland Clinic, of New York Presbyterian Mount Sinai, Cedars-Sinai, you know, right up to the chief medical officers, the chief physicians, and the CEOs in many ca…”
Sep 5, 2025 positive
Nadler: Treating enterprise users as consumers accelerates adoption across skeptical industries
“While medicine is obviously very specific, the human psychology is not. And everything that was true and that we've seen through the sort of hyper pace consumer internet growth curve adoption by the most traditionally skeptical knowledge workers shows that in …”
Sep 5, 2025 bullish
Nadler: AI tools will bridge specialist medical care gaps in rural US
“I think increasingly, certainly in rural areas and healthcare deserts at the fringes and edges of healthcare in the United States. That's absolutely how certainly open evidence is being used and how I think broadly is going to be used at least to sort of bridg…”
Sep 5, 2025 bullish
Nadler: OpenEvidence is NEJM's largest traffic referrer after Google
“You know, I think we're one of the largest sources of referral traffic to the England Journal of Medicine after Google. The rankings, I don't know if they're number two or three or four, but we're one of the largest sources of referral traffic to our partner i…”
Sep 5, 2025 positive
Sep 5, 2025 neutral
Nadler: The idea for OpenEvidence is completely obvious, not uniquely creative
“But you need to find this sort of perfect storm of things, and it has very little to do with ideas. You know, the idea for open evidence is the most obvious idea in the world. It's the same as, it's no more creative than let's go to the moon. Let's do somethin…”
Sep 5, 2025 positive
Nadler: OpenEvidence is probably the only AI company in high-stakes clinical decisions
“We're probably the only company working at the tip of that spear. Most people have self-selected themselves out of the problem of high stakes, clinical decision-making certainly through an AI lens because they view it as ambitious.”
Sep 5, 2025 bullish
Sep 5, 2025 positive
Sep 5, 2025 positive
Nadler: OpenEvidence frequently generates patient handouts and insurance appeal letters
“Encourage physicians to use open evidence to generate patient handouts, and that's actually a very widely used secondary. It's mainly clinical report, but we have all these secondary use cases like prior authorization letters and insurance appeal letters, and …”